Pre-made Etaracizumab benchmark antibody ( Whole mAb, anti-ITGAV_ITGB3 therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-195
Pre-made Etaracizumab benchmark antibody (Whole mAb, anti-ITGAV_ITGB3 therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Etaracizumab, also known as etaratuzumab, MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer. It is manufactured by MedImmune.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Etaracizumab biosimilar, Whole mAb, Anti-ITGAV;ITGB3 Antibody: Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Applied Molecular Evolution;MedImmune|
|Conditions Discontinued||Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis|